by IR Team | Mar 16, 2021 | News
Would an “immunity passport” be more effective? The vaccines are still in the early stages of being studied, but they’re thought to be highly effective. However, there are questions that remain. For example, it’s not clear if a vaccinated person who gets the virus can...
by IR Team | Mar 9, 2021 | News
The Company conducted two studies, one in partnership with the Company’s manufacturing partner Empowered Diagnostics and the second in partnership with a top accredited university medical center. The main goal of these studies was to identify the ability of operators...
by IR Team | Mar 9, 2021 | News
Vaccine boosters could have a dual positive impact on the Covid-19 pandemic. They can boost the immune response against the original SARS-CoV-2 virus, as well as provide methods to overcome the emerging viral variants that could render existing vaccines ineffective....
by IR Team | Mar 8, 2021 | News
AXIM Biotechnologies (OTCQB:AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies. The test aims to help understand COVID-19 immunity, validate vaccine’s...
by IR Team | Feb 28, 2021 | News
The CDC estimates that in the past 20 years, vaccines have saved more that 21 million lives. There are many different types of vaccines that provide protection against infectious diseases. Some examples of diseases for which vaccines elicit protective immunity include...
by IR Team | Feb 7, 2021 | News
John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first...